Background Previous studies have reported that oxidative stress contributes to obesity characterized by adipocyte hypertrophy. However, mechanism has not been studied extensively. In the current study, we evaluated role of extracellular vimentin secreted by oxidized low-density lipoprotein (oxLDL) in energy metabolism in adipocytes.
Methods We treated 3T3-L1-derived adipocytes with oxLDL and measured vimentin which was secreted in the media. We evaluated changes in uptake of glucose and free fatty acid, expression of molecules functioning in energy metabolism, synthesis of adenosine triphosphate (ATP) and lactate, markers for endoplasmic reticulum (ER) stress and autophagy in adipocytes treated with recombinant vimentin.
Results Adipocytes secreted vimentin in response to oxLDL. Microscopic evaluation revealed that vimentin treatment induced increase in adipocyte size and increase in sizes of intracellular lipid droplets with increased intracellular triglyceride. Adipocytes treated with vimentin showed increased uptake of glucose and free fatty acid with increased expression of plasma membrane glucose transporter type 1 (GLUT1), GLUT4, and CD36. Vimentin treatment increased transcription of GLUT1 and hypoxia-inducible factor 1α (Hif-1α) but decreased GLUT4 transcription. Adipose triglyceride lipase (ATGL), peroxisome proliferator-activated receptor γ (PPARγ), sterol regulatory element-binding protein 1 (SREBP1), diacylglycerol O-acyltransferase 1 (DGAT1) and 2 were decreased by vimentin treatment. Markers for ER stress were increased and autophagy was impaired in vimentin-treated adipocytes. No change was observed in synthesis of ATP and lactate in the adipocytes treated with vimentin.
Conclusion We concluded that extracellular vimentin regulates expression of molecules in energy metabolism and promotes adipocyte hypertrophy. Our results show that vimentin functions in the interplay between oxidative stress and metabolism, suggesting a mechanism by which adipocyte hypertrophy is induced in oxidative stress.
Diabetic kidney disease (DKD) is the major cause of end-stage kidney disease. However, only renin-angiotensin system inhibitor with multidisciplinary treatments is effective for DKD. In 2019, sodium-glucose cotransporter 2 (SGLT2) inhibitor showed efficacy against DKD in Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, adding a new treatment option. However, the progression of DKD has not been completely controlled. The patients with transient exposure to hyperglycemia develop diabetic complications, including DKD, even after normalization of their blood glucose. Temporary hyperglycemia causes advanced glycation end product (AGE) accumulations and epigenetic changes as metabolic memory. The drugs that improve metabolic memory are awaited, and AGE inhibitors and histone modification inhibitors are the focus of clinical and basic research. In addition, incretin-related drugs showed a renoprotective ability in many clinical trials, and these trials with renal outcome as their primary endpoint are currently ongoing. Hypoxia-inducible factor prolyl hydroxylase inhibitors recently approved for renal anemia may be renoprotective since they improve tubulointerstitial hypoxia. Furthermore, NF-E2–related factor 2 activators improved the glomerular filtration rate of DKD patients in Bardoxolone Methyl Treatment: Renal Function in chronic kidney disease/Type 2 Diabetes (BEAM) trial and Phase II Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes (TSUBAKI) trial. Thus, following SGLT2 inhibitor, numerous novel drugs could be utilized in treating DKD. Future studies are expected to provide new insights.
Citations
Citations to this article as recorded by
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence Xiao-Mei Chen, Gui-Xuan Lin, Xue Wang, Hong-Yan Ma, Ru-Shang Wang, Shu-Mei Wang, Dan Tang Journal of Ethnopharmacology.2023; 302: 115860. CrossRef
Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018 Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585. CrossRef
A Narrative Review of New Treatment Options for Diabetic Nephropathy Aadhira Pillai, Darshna Fulmali Cureus.2023;[Epub] CrossRef
Shenkang recipe alleviates renal aging in diabetic kidney disease by interfering with the lysine-specific demethylase KDM6B to modulate the PPAR-γ signaling pathway Anna Zuo, Jiarun Xie, Junqiao Shao, Shuyu Li, Haoyu Lin, Shaoting Wang, Wei Sun, Jinjin Xia, Weiqiang Jiang, Jia Sun, Ming Wang Pharmacological Research - Modern Chinese Medicine.2023; 6: 100216. CrossRef
miR-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway Ping Tang, Yushan Xu, Jingrong Zhang, Juanli Nan, Ruxian Zhong, Jingmei Luo, Dazhi Xu, Shaoqing Shi, Lihua Zhang Biochemical and Biophysical Research Communications.2023; 648: 50. CrossRef
miR‐124‐3p improves mitochondrial function of renal tubular epithelial cells in db/db mice Luqun Liang, Chunxin Wo, Yao Yuan, Hongjuan Cao, Wanlin Tan, Xingcheng Zhou, Dan Wang, Rongyu Chen, Mingjun Shi, Fan Zhang, Ying Xiao, Lingling Liu, Yuxia Zhou, Tian Zhang, Yuanyuan Wang, Bing Guo The FASEB Journal.2023;[Epub] CrossRef
Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases Satoshi Yamasaki, Takahiko Horiuchi Hematology Reports.2023; 15(1): 180. CrossRef
Diagnostic significance of hsa_circ_0000146 and hsa_circ_0000072 biomarkers for Diabetic Kidney Disease in patients with type 2 diabetes mellitus Amul Badr, Omayma Elkholy, Mona Said, Sally Fahim, Mohamed El-Khatib, Dina Sabry, Radwa Gaber Journal of Medical Biochemistry.2023; 42(2): 239. CrossRef
The emerging insight into E3 ligases as the potential therapeutic target for diabetic kidney disease Vivek Akhouri, Syamantak Majumder, Anil Bhanudas Gaikwad Life Sciences.2023; 321: 121643. CrossRef
Klotho’s impact on diabetic nephropathy and its emerging connection to diabetic retinopathy Anqi Tang, Yu Zhang, Ling Wu, Yong Lin, Lizeyu Lv, Liangbin Zhao, Bojun Xu, Youqun Huang, Mingquan Li Frontiers in Endocrinology.2023;[Epub] CrossRef
Differences and Clinical Significance of Serum 25-Hydroxyvitamin D3 and Vasohibin-1 (VASH-1) Levels in Patients with Diabetic Nephropathy and Different Renal Injuries Hui Liu, Dongyan Wang, Jingnan Tang, Linlin Yu, Shanshan Su Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1085. CrossRef
Medial Arterial Calcification and the Risk of Amputation of Diabetic Foot Ulcer in Patients With Diabetic Kidney Disease Joon Myeong So, Ji Ho Park, Jin Gyeong Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Chul Hyun Park, Woo-Sung Yun, Tae-Gon Kim, Woong Kim, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee Journal of Korean Medical Science.2023;[Epub] CrossRef
Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy Baranca Buijsers, Marjolein Garsen, Mark de Graaf, Marinka Bakker-van Bebber, Chunming Guo, Xue Li, Johan van der Vlag Frontiers in Pharmacology.2023;[Epub] CrossRef
Influence of non-alcoholic steatohepatitis on the renal functional status in patients with type 2 diabetes and diabetic kidney disease Z.Ya. Кotsiubiichuk, O.S. Khukhlina, А.А. Аntoniv, O.Ye. Mandryk INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(2): 100. CrossRef
Roles of extracellular vesicles in ageing-related chronic kidney disease: Demon or angel Siqi Yin, Zixuan Zhou, Peiwen Fu, Chaoying Jin, Peipei Wu, Cheng Ji, Yunjie Shan, Linru Shi, Min Xu, Hui Qian Pharmacological Research.2023; 193: 106795. CrossRef
Role of Natural and Synthetic Compounds in Modulating NRF2/KEAP1 Signaling Pathway in Prostate Cancer Giovanni Tossetta, Sonia Fantone, Daniela Marzioni, Roberta Mazzucchelli Cancers.2023; 15(11): 3037. CrossRef
Risk factors for heart, cerebrovascular, and kidney diseases: evaluation of potential side effects of medications to control hypertension, hyperglycemia, and hypercholesterolemia Kazumitsu Nawata Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef
Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study) Marie Møller, Rikke Borg, Iain Bressendorff, Lisbeth N Fink, Eva Gravesen, Karina Haar Jensen, Torben Hansen, Dorrit Krustrup, Frederik Persson, Peter Rossing, Frederikke E Sembach, Anne C B Thuesen, Ditte Hansen BMJ Open.2023; 13(6): e072216. CrossRef
Oral Chinese patent medicines for diabetic kidney disease: An overview of systematic reviews Xue Xue, Ke-ying Li, Shang-zhi Liu, Jia-xuan Li, Xin-yan Jin, Xue-han Liu, La-mei Lin, Xin-rong Zou, Chun-li Lu, Fang-fang Zhao, Jian-ping Liu, Xiao-qin Wang European Journal of Integrative Medicine.2023; 61: 102269. CrossRef
Recent Advances in Proteinuric Kidney Disease/Nephrotic Syndrome: Lessons from Knockout/Transgenic Mouse Models Ryosuke Saiki, Kan Katayama, Kaoru Dohi Biomedicines.2023; 11(7): 1803. CrossRef
Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes Imari Mimura, Masaomi Nangaku Kidney International.2023; 104(6): 1048. CrossRef
Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress Ming Chen, Yao Chen, Wenhui Zhu, Xiaoming Yan, Jing Xiao, Peiqing Zhang, Peng Liu, Ping Li Biomedicine & Pharmacotherapy.2023; 165: 115088. CrossRef
A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus FNU Jyotsna, Kamran Mahfooz, Tirath Patel, FNU Parshant, Fnu Simran, Fnu Harsha, Fnu Neha, Dev Jyotishna, Dipesh Mishra, Sirjana Subedi, Mahima Khatri, Satesh Kumar, Giustino Varrassi Cureus.2023;[Epub] CrossRef
Molecular implications of glycosaminoglycans in diabetes pharmacotherapy Tanya Waseem, Madiha Ahmed, Tausif Ahmed Rajput, Mustafeez Mujtaba Babar International Journal of Biological Macromolecules.2023; 247: 125821. CrossRef
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation Jasna Klen, Vita Dolžan Pharmaceutics.2023; 15(7): 1995. CrossRef
CUL3 induces mitochondrial dysfunction via MRPL12 ubiquitination in renal tubular epithelial cells Xingzhao Ji, Xiaoli Yang, Xia Gu, Lingju Chu, Shengnan Sun, Jian Sun, Peng Song, Qian Mu, Ying Wang, Xiaoming Sun, Dun Su, Tong Su, Shaoshuai Hou, Yao Lu, Chen Ma, Mingqiang Liu, Tianyi Zhang, Weiying Zhang, Yi Liu, Qiang Wan The FEBS Journal.2023; 290(22): 5340. CrossRef
HP1 induces ferroptosis of renal tubular epithelial cells through NRF2 pathway in diabetic nephropathy Chuanqiang Zhou, Min Wu, Gaolun Liu, Li Zhou Open Life Sciences.2023;[Epub] CrossRef
A Review of the Potential of Nuclear Factor [Erythroid-Derived 2]-like 2 Activation in Autoimmune Diseases Ilker Ates, Ayşe Didem Yılmaz, Brigitta Buttari, Marzia Arese, Luciano Saso, Sibel Suzen Brain Sciences.2023; 13(11): 1532. CrossRef
Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the “gut-kidney axis” Zhen Shen, Tao Cui, Yao Liu, Shuai Wu, Cong Han, Jie Li Phytomedicine.2023; 121: 155129. CrossRef
The relevance of the non-invasive biomarkers lncRNA GAS5/miR-21 ceRNA regulatory network in the early identification of diabetes and diabetic nephropathy He Sun, Tong Chen, Xin Li, Yonghong Zhu, Shuang Zhang, Ping He, Yali Peng, Qiuling Fan Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy Jian Lu, Xue Qi Li, Pei Pei Chen, Jia Xiu Zhang, Liang Liu, Gui Hua Wang, Xiao Qi Liu, Ting Ting Jiang, Meng Ying Wang, Wen Tao Liu, Xiong Zhong Ruan, Kun Ling Ma JCI Insight.2023;[Epub] CrossRef
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy Samarth Dwivedi, Atharva Chavan, Atish T. Paul Drug Discovery Today.2023; 28(10): 103754. CrossRef
Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxia Tomotaka Yamazaki, Imari Mimura, Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku Physiological Reports.2023;[Epub] CrossRef
GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis Xiang Li, Xiao Jiang, Mei Jiang, Zhi-feng Wang, Tao Zhao, Si-ming Cao, Qiu-Mei Li Acta Diabetologica.2023;[Epub] CrossRef
Highly Sensitive, Portable Detection System for Multiplex Chemiluminescence Analysis Yannan Yu, Wei Nie, Kaiqin Chu, Xi Wei, Zachary J. Smith Analytical Chemistry.2023; 95(39): 14762. CrossRef
From normal population to prediabetes and diabetes: study of influencing factors and prediction models Di Gong, Xiaohong Chen, Lin Yang, Yongjian Zhang, Qianqian Zhong, Jing Liu, Chen Yan, Yongjiang Cai, Weihua Yang, Jiantao Wang Frontiers in Endocrinology.2023;[Epub] CrossRef
Diabetes Monitoring through Urine Analysis Using ATR-FTIR Spectroscopy and Machine Learning Sajid Farooq, Denise Maria Zezell Chemosensors.2023; 11(11): 565. CrossRef
Cardiovascular autonomic neuropathy and incident diabetic kidney disease in patients with type 2 diabetes Ji Eun Jun, Min Sun Choi, Jae Hyeon Kim Diabetes Research and Clinical Practice.2022; 184: 109181. CrossRef
Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice Martin Ho Yin Yeung, Ka Long Leung, Lai Yuen Choi, Jung Sun Yoo, Susan Yung, Pui-Kin So, Chi-Ming Wong Frontiers in Pharmacology.2022;[Epub] CrossRef
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo Kidney Research and Clinical Practice.2022; 41(2): 136. CrossRef
Evolving Type 2 diabetes management focuses on clinical outcomes Caroline Fenton, Connie Kang Drugs & Therapy Perspectives.2022; 38(4): 165. CrossRef
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease Chan-Young Jung, Tae-Hyun Yoo Diabetes & Metabolism Journal.2022; 46(2): 181. CrossRef
Critical shear stress of red blood cells as a novel integrated biomarker for screening chronic kidney diseases in cases of type 2 diabetes Il Rae Park, Jimi Choi, Eun Young Ha, Seung Min Chung, Jun Sung Moon, Sehyun Shin, Sin Gon Kim, Kyu Chang Won Clinical Hemorheology and Microcirculation.2022; 81(4): 293. CrossRef
Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells Donghee Kim, Ga-Young Nam, Eunhui Seo, Hee-Sook Jun Journal of Biomedical Science.2022;[Epub] CrossRef
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1 Yuji Oe, Volker Vallon Kidney and Dialysis.2022; 2(2): 349. CrossRef
Dapagliflozin for the treatment of chronic kidney disease Yu Kurata, Masaomi Nangaku Expert Review of Endocrinology & Metabolism.2022; 17(4): 275. CrossRef
Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease Javier Donate-Correa, María Dolores Sanchez-Niño, Ainhoa González-Luis, Carla Ferri, Alberto Martín-Olivera, Ernesto Martín-Núñez, Beatriz Fernandez-Fernandez, Víctor G Tagua, Carmen Mora-Fernández, Alberto Ortiz, Juan F Navarro-González Clinical Kidney Journal.2022; 15(12): 2200. CrossRef
Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells Himanshu Sankrityayan, Ajinath Kale, Vishwadeep Shelke, Anil Bhanudas Gaikwad Archives of Physiology and Biochemistry.2022; : 1. CrossRef
Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress Debra Dorotea, Songling Jiang, Eun Seon Pak, Jung Beom Son, Hwan Geun Choi, Sung-Min Ahn, Hunjoo Ha Experimental & Molecular Medicine.2022; 54(8): 1086. CrossRef
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics Nam Hoon Kim, Nan Hee Kim Diabetes & Metabolism Journal.2022; 46(4): 543. CrossRef
Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease Sungmin Kim, Jung Nam An, Young Rim Song, Sung Gyun Kim, Hyung Seok Lee, AJin Cho, Jwa-Kyung Kim, Tomislav Bulum PLOS ONE.2022; 17(8): e0273004. CrossRef
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives Daniela Maria Tanase, Evelina Maria Gosav, Madalina Ioana Anton, Mariana Floria, Petronela Nicoleta Seritean Isac, Loredana Liliana Hurjui, Claudia Cristina Tarniceriu, Claudia Florida Costea, Manuela Ciocoiu, Ciprian Rezus Biomolecules.2022; 12(9): 1227. CrossRef
Preventive and healing effect of high dosing grape seed flour on CKD patients of various stages and aetiologies Wiem Bejaoui, Mohamed Mahmoudi, Kamel Charradi, Monia Abbes-Belhadj, Habib Boukhalfa, Mossadok Ben-Attia, Ferid Limam, Ezzedine Aouani Biomarkers.2022; 27(8): 795. CrossRef
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, James R Sowers, Wenshuo Wang, Junbo Ge, Jun Ren, Yingmei Zhang, Wei-Ping Jia Journal of Molecular Cell Biology.2022;[Epub] CrossRef
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases Wei Huang, Yi-Yuan Chen, Zi-Qi Li, Fang-Fang He, Chun Zhang International Journal of Molecular Sciences.2022; 23(18): 10882. CrossRef
Serum isthmin-1 levels are positively and independently correlated with albuminuria in patients with type 2 diabetes mellitus Chuan Wang, Mingyue Xu, Ruiying Feng, Lei Zhang, Xiaofei Yin, Ruoqi Feng, Kai Liang, Jinbo Liu BMJ Open Diabetes Research & Care.2022; 10(5): e002972. CrossRef
hucMSC-sEVs-Derived 14-3-3ζ Serves as a Bridge between YAP and Autophagy in Diabetic Kidney Disease Siqi Yin, Wanzhu Liu, Cheng Ji, Yuan Zhu, Yunjie Shan, Zixuan Zhou, Wenya Chen, Leilei Zhang, Zixuan Sun, Wenqin Zhou, Hui Qian, Chaoliang Tang Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef
Adenosine receptors as emerging therapeutic targets for diabetic kidney disease Eun Seon Pak, Jin Joo Cha, Dae Ryong Cha, Keizo Kanasaki, Hunjoo Ha Kidney Research and Clinical Practice.2022; 41(Suppl 2): S74. CrossRef
REDD1 Ablation Attenuates the Development of Renal Complications in Diabetic Mice Siddharth Sunilkumar, Esma I. Yerlikaya, Allyson L. Toro, William P. Miller, Han Chen, Kebin Hu, Scot R. Kimball, Michael D. Dennis Diabetes.2022; 71(11): 2412. CrossRef
The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease Huixia Liu, Yujuan Li, Jing Xiong Molecules.2022; 27(21): 7318. CrossRef
Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease Anna M. Drake, Melinda T. Coughlan, Claus T. Christophersen, Matthew Snelson Nutrients.2022; 14(21): 4547. CrossRef
Aggravated renal fibrosis is positively associated with the activation of HMGB1-TLR2/4 signaling in STZ-induced diabetic mice Yan Yuan, Yuanxia Liu, Mengyao Sun, Huijing Ye, Yuchen Feng, Zhenzhen Liu, Lingyu Pan, Hongbo Weng Open Life Sciences.2022; 17(1): 1451. CrossRef
Single-cell multiomics reveals the complexity of TGFβ signalling to chromatin in iPSC-derived kidney organoids Jessica L. Davis, Ciaran Kennedy, Shane Clerkin, Niall J. Treacy, Thomas Dodd, Catherine Moss, Alison Murphy, Derek P. Brazil, Gerard Cagney, Dermot F. Brougham, Rabi Murad, Darren Finlay, Kristiina Vuori, John Crean Communications Biology.2022;[Epub] CrossRef
Oxidized Albumin: Evaluation of Oxidative Stress as a Marker for the Progression of Kidney Disease Hiroshi Watanabe Biological and Pharmaceutical Bulletin.2022; 45(12): 1728. CrossRef
Whether Renal Pathology Is an Independent Predictor for End-Stage Renal Disease in Diabetic Kidney Disease Patients with Nephrotic Range Proteinuria: A Biopsy-Based Study Tingli Wang, Junlin Zhang, Yiting Wang, Lijun Zhao, Yucheng Wu, Honghong Ren, Yutong Zou, Rui Zhang, Huan Xu, Zhonglin Chai, Mark Cooper, Jie Zhang, Fang Liu Journal of Clinical Medicine.2022; 12(1): 88. CrossRef
What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances Kimio Watanabe, Emiko Sato, Eikan Mishima, Mariko Miyazaki, Tetsuhiro Tanaka International Journal of Molecular Sciences.2022; 24(1): 570. CrossRef
Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis Zhiyue Zhu, Qi Zhang, Le Liu, Pengjie Bao, Shilin Liu, Chaoqun Song, Wenbo Yang, Zheng Nan Medicine.2022; 101(49): e31490. CrossRef
Cudrania tricuspidata Root Extract Prevents Methylglyoxal-Induced Inflammation and Oxidative Stress via Regulation of the PKC-NOX4 Pathway in Human Kidney Cells Donghee Kim, Jayeon Cheon, Haelim Yoon, Hee-Sook Jun, Evangelia Dounousi Oxidative Medicine and Cellular Longevity.2021; 2021: 1. CrossRef
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control Tomoaki Takata, Hajime Isomoto International Journal of Molecular Sciences.2021; 22(9): 4374. CrossRef
HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review Kiichi Hirota Biomedicines.2021; 9(5): 468. CrossRef
Nephropathie bei Diabetes Roland E. Schmieder CardioVasc.2021; 21(3): 31. CrossRef
Clinical Predictors of Nondiabetic Kidney Disease in Patients with Diabetes: A Single-Center Study Francesco Fontana, Rossella Perrone, Francesco Giaroni, Gaetano Alfano, Silvia Giovanella, Giulia Ligabue, Riccardo Magistroni, Gianni Cappelli, Udeme Ekrikpo International Journal of Nephrology.2021; 2021: 1. CrossRef
Activated Histone Acetyltransferase p300/CBP-Related Signalling Pathways Mediate Up-Regulation of NADPH Oxidase, Inflammation, and Fibrosis in Diabetic Kidney Alexandra-Gela Lazar, Mihaela-Loredana Vlad, Adrian Manea, Maya Simionescu, Simona-Adriana Manea Antioxidants.2021; 10(9): 1356. CrossRef
Plasma and urine biomarkers in chronic kidney disease: closer to clinical application Azadeh Zabetian, Steven G. Coca Current Opinion in Nephrology & Hypertension.2021; 30(6): 531. CrossRef
Therapeutic effect and mechanism of combined use of FGF21 and insulin on diabetic nephropathy Fanrui Meng, Yukai Cao, Mir Hassan Khoso, Kai Kang, Guiping Ren, Wei Xiao, Deshan Li Archives of Biochemistry and Biophysics.2021; 713: 109063. CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe Frontiers in Pharmacology.2021;[Epub] CrossRef
Transcription Factor ChREBP Mediates High Glucose-Evoked Increase in HIF-1α Content in Epithelial Cells of Renal Proximal Tubules Aleksandra Owczarek, Katarzyna B. Gieczewska, Robert Jarzyna, Zuzanna Frydzinska, Katarzyna Winiarska International Journal of Molecular Sciences.2021; 22(24): 13299. CrossRef
The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus V.I. Katerenchuk INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(8): 624. CrossRef